Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Alp Ozpinar

Neurological Surgery Springfield, OR Medical Doctor

NPI 1417397233 CMS profile 2786645

3377 Riverbend Dr, Springfield, OR 97477

Open in the dashboard

General payments

$234,998

527 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alp Ozpinar of Springfield, OR is reported in the CMS Open Payments database as having received $234,998 across 527 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Neurological Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $136,087 181
2024 General $80,377 218
2023 General $6,775 66
2022 General $11,496 60
2021 General $133 1
2020 General $130 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alp Ozpinar
  • Neurological Surgery median
  • Middle half of Neurological Surgery
  • National median

In program year 2025, general payments to Alp Ozpinar were reported at $136,087. Among 5,467 Neurological Surgery profiles paid that year, the median was $596 and the middle half received between $159 and $3,102.

Show as a table
Year Alp Ozpinar Neurological Surgery median Middle half National median
2019 $0 $582 $138–$3,006 $163
2020 $130 $294 $76–$2,174 $114
2021 $133 $387 $105–$2,432 $132
2022 $11,496 $542 $139–$2,989 $149
2023 $6,775 $534 $145–$2,697 $160
2024 $80,377 $574 $155–$3,046 $164
2025 $136,087 $596 $159–$3,102 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Alphatec Spine, Inc $98,310 284 payments
  2. SI-BONE, Inc. $50,658 60 payments
  3. Cerapedics, Inc. $43,331 48 payments
  4. Globus Medical, Inc. $18,484 40 payments
  5. Highridge Medical LLC $11,273 11 payments
  6. Orthofix Medical, Inc. $8,225 34 payments
  7. NuVasive, Inc. $1,869 23 payments
  8. Medtronic, Inc. $1,207 7 payments
  9. Stryker Corporation $506 5 payments
  10. MML US, Inc. $251 2 payments
  11. Other $886 13 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Consulting Fee $168,345 49 payments
  2. Travel and Lodging $37,290 113 payments
  3. Food and Beverage $29,363 365 payments
Products named General payments · program years 2020–2025
  1. Other - Miscellaneous $62,566 90 payments
  2. IFUSE IMPLANT SYSTEM $50,131 54 payments
  3. I-FACTOR PEPTIDE ENHANCED BONE GRAFT $43,331 48 payments
  4. IdentiTi $12,469 6 payments
  5. AMP $11,000 1 payment
  6. Spine-None $10,506 6 payments
  7. ELSA $7,875 2 payments
  8. Excelsius Robotics System $7,664 12 payments
  9. Biologics $5,765 62 payments
  10. Invictus OPEN $5,726 33 payments
  11. Other $25,124 174 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

112

Median for Neurosurgery: 83

Drug cost

$1,072

Median for Neurosurgery: $872

Branded share of claims

0%

Median for Neurosurgery: 16.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Pregabalin Generic 23 $422
Methocarbamol Generic 35 $268
Oxycodone Hcl Generic 41 $266
Methylprednisolone Generic 13 $117

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,779 Part D prescribers listed as Neurosurgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 67 billing codes

Paid by Medicare

$366,751

Medicare's payments for the services billed

Medicare patients

293

Average age 73

Services billed

1,319

152 women, 141 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 71%
Depression 27%
Diabetes 26%
Chronic kidney disease 21%
Osteoporosis 18%
Ischemic heart disease 17%
COPD 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

527 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record